Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2. Chronic kidney disease risk tool application.

Published byRussell Harry Kennedy Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 2. Chronic kidney disease risk tool application."— Presentation transcript:

1 Figure 2. Chronic kidney disease risk tool application.
From: Implementation of a scalable, web-based, automated clinical decision support risk-prediction tool for chronic kidney disease using C-CDA and application programming interfaces J Am Med Inform Assoc. 2017;24(6): doi: /jamia/ocx065 J Am Med Inform Assoc | © The Author Published by Oxford University Press on behalf of the American Medical Informatics Association.This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence ( which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work properly cited. For commercial re-use, please contact

2 Figure 3. Clinical decision support link and rollover text on LMR patient summary page.
From: Implementation of a scalable, web-based, automated clinical decision support risk-prediction tool for chronic kidney disease using C-CDA and application programming interfaces J Am Med Inform Assoc. 2017;24(6): doi: /jamia/ocx065 J Am Med Inform Assoc | © The Author Published by Oxford University Press on behalf of the American Medical Informatics Association.This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence ( which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work properly cited. For commercial re-use, please contact

3 Figure 1. Methods for delivering online clinical decision support.
From: Implementation of a scalable, web-based, automated clinical decision support risk-prediction tool for chronic kidney disease using C-CDA and application programming interfaces J Am Med Inform Assoc. 2017;24(6): doi: /jamia/ocx065 J Am Med Inform Assoc | © The Author Published by Oxford University Press on behalf of the American Medical Informatics Association.This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence ( which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work properly cited. For commercial re-use, please contact

Download ppt "Figure 2. Chronic kidney disease risk tool application."

Similar presentations

Figure 1 Overall design of Query Health

Figure 1 Overall design of Query Health
Fig. 4. Carer ratings of executive functioning (Dysexecutive Questionnaire) and memory (Memory Checklist) in the 3 groups at the beginning and end of the.

Fig. 4. Carer ratings of executive functioning (Dysexecutive Questionnaire) and memory (Memory Checklist) in the 3 groups at the beginning and end of the.
Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.
Figure 1: AFHIR Observation Resource Definition for systolic blood pressure with example in JSON. From: SMART on FHIR: a standards-based, interoperable.

Figure 1: AFHIR Observation Resource Definition for systolic blood pressure with example in JSON. From: SMART on FHIR: a standards-based, interoperable.
Fig. 1. Significant clusters in the amygdala and dlPFC, four-way interaction effect (group by valence by temperature by time), small volume corrected.

Fig. 1. Significant clusters in the amygdala and dlPFC, four-way interaction effect (group by valence by temperature by time), small volume corrected.
From: Dynamic De/Centralization in Canada, 1867–2010

From: Dynamic De/Centralization in Canada, 1867–2010
Figure 3: (a and b) Preoperative contrast-eCT

Figure 3: (a and b) Preoperative contrast-eCT
Figure 1 Proportion of criteria chosen (as percentages, grouped into issues). From: Developing national obesity policy in middle-income countries: a case.

Figure 1 Proportion of criteria chosen (as percentages, grouped into issues). From: Developing national obesity policy in middle-income countries: a case.
Figure 2. Number of cases required in a Mendelian randomization analysis with a binary outcome and a single instrumental variable for 80% power with a.

Figure 2. Number of cases required in a Mendelian randomization analysis with a binary outcome and a single instrumental variable for 80% power with a.
J Exp Bot. 2017;68(17): doi: /jxb/erx352

J Exp Bot. 2017;68(17): doi: /jxb/erx352
Fig. 1. Scheme for classifying renal function without access to laboratory test results. *Renal-specific drugs: phosphate binders (ATC codes.

Fig. 1. Scheme for classifying renal function without access to laboratory test results. *Renal-specific drugs: phosphate binders (ATC codes.
Fig 1 The CONSORT participant flow diagram for primary endpoints.

Fig 1 The CONSORT participant flow diagram for primary endpoints.
Figure 5: Three-dimensional reconstruction of the CT scan showing the trapped air in the head and neck region. From: Distinct subcutaneous emphysema following.

Figure 5: Three-dimensional reconstruction of the CT scan showing the trapped air in the head and neck region. From: Distinct subcutaneous emphysema following.
From: Learning by Working in Big Cities

From: Learning by Working in Big Cities
From: THE FALLACIES OF PATENT-HOLDUP THEORY

From: THE FALLACIES OF PATENT-HOLDUP THEORY
Fig. 1. Trial structure for the experimental task.

Fig. 1. Trial structure for the experimental task.
Fig. 1 Nodes in a conceptual knowledge graph

Fig. 1 Nodes in a conceptual knowledge graph
Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.
From: Nutrition and brain development in early life

From: Nutrition and brain development in early life
From: Epidemiology of Inappropriate Empiric Antibiotic Therapy for Bacteremia Based on Discordant In vitro Susceptibilities: Risk factors and Taxon-level.

From: Epidemiology of Inappropriate Empiric Antibiotic Therapy for Bacteremia Based on Discordant In vitro Susceptibilities: Risk factors and Taxon-level.

Similar presentations

Ads by Google